BREAKTHROUGH TREATMENT FOR A COMMON FRACTURE

MIDSHAFT CLAVICLE FRACTURES ARE COMMON

The clavicle is one of the most commonly fractured bones in the human body, and the majority of those fractures are midshaft.

LEGACY
TREATMENTS
HAVE BEEN
SUBOPTIMAL

Historically midshaft clavicle fractures have been treated non-operatively or with plates. Both approaches, while appropriate for some cases, have significant drawbacks. Various intramedullary devices have also been tried, but fallen short.

NON-OPERATIVE

– Non-unions, malunions
– Shortening
– Slower recovery
– Initial compromised function
– Poor aesthetics

PLATES

  • Large incision
  • Supraclavicular neuropathy
  • Hardware irritation requiring secondary intervention
  • Scarring, poor aesthetics
  • Risk of refracture after removal

LEGACY INTRAMEDULLARY DEVICES

  • Prominent protruding hardware
  • Telescoping, migration
  • Wound breakdown
  • Secondary shortening
  • Frequent secondary interventions
  • Indicated for a small subset of fractures

THE ANSWER
IS THE ANSER

Designed specifically for the surgical management of midshaft clavicle fractures, the Anser Clavicle Pin has the potential to disrupt the market and become the leading treatment in the near future. It solves multiple problems associated with legacy therapies, facilitating excellent clinical and aesthetic outcomes with minimal risk of infection, or need for secondary interventions.

  • Minimally invasive procedure
  • No bump, no droop, no large scar
  • Excellent union rates 
  • Excellent functional outcomes 
  • Allows for early rehab, return to activity 
  • Reduced healthcare cost, time away from work and family

MILESTONES AND FUTURE STATE

Prototype developed in partnership with BAAT Medical BV, Netherlands

Patents granted in USA, Europe, China, Australia, India and South Africa

Multiple Dutch and EU grants obtained

2020 CE certification and 510(k) approval obtained

2023 Introduction at AAOS, US distribution solidified

2024 Dedicated effort to increase US market share

2025 Global expansion initiatives

2028 Anser Clavicle Pin captures 5% of market

POISED FOR SUCCESS

The Anser Clavicle Pin is positioned for global success in the orthopedic and trauma markets. It has been significantly advanced and de-risked, with US and European regulatory approvals, multiple patents, fully validated manufacturing, well-rounded team, strong reimbursement, scalability and scientific data.

Regulatory
Approvals
CE & FDA
Enforceable
Patents
US, EU, CH,
AU, SA, IN
Strong
Reimbursement
No payer coverage concerns
Clinical
Evidence

Peer-reviewed
publications;
Ongoing
prospective trials

Top-tier
Partner
Operations
infrastructure,
US & EU
World-class
Advisory Board